国产成人精品高清久久_好姑娘影视在线观看高清_99久久久久久久久_欧美涩涩网_久久国产精品91_9色网站

英國,Oxford Pharmascience,  
牛津制藥科學

Founded in February 2008 by a team of entrepreneurs with former corporate experience in consumer healthcare, we have established a platform of core technologies and products by acquisition, in-house development and in-licensing.

We operate from the United Kingdom working with a range of partners in pharmaceutical technology, drug delivery and manufacturing to provide a unique service by bringing together leading edge science with innovative product development to meet patient and market needs.

Our Business Model
OXP Group Plc develops advanced yet practical pharmaceutical technologies to enable reformulation that adds value to off patent and soon to be off patent drugs. The company does not manufacture or sell its own pharmaceutical products but instead seeks to license its technologies to a network of partners, mainly leading pharmaceutical companies with Rx and OTC branded portfolios. These partners use our technologies to reposition their products helping them sustain market share and profitability by delivering improved health outcomes and/or clinical profiles via reformulated versions of the same API.

OXP develops platform technologies that have application across multiple drug categories and can be leveraged across a broad range of reformulation problems. This business model allows us to provide solutions across the industry and fund the ongoing development of cutting edge technologies to better serve the needs of our partners. The partner companies who adopt our technology pay an up-front licence fee followed by development milestone payments and then royalties on finished products sold using the technology. OXP invests the upfront licence fee to optimise product development and to ensure seamless technology transfer to the pharmaceutical partner.